Shares of Jubilant Ingrevia closed up 8.2% at ₹631 after the company announced Q2 net profit of ₹111.4 crore, up 61.4% YoY, beating the ₹92.5 crore consensus. NewPARA Revenue for the September quarter hit ₹1,394.2 crore, a 24.4% jump from ₹1,121 crore a year earlier, and eclipsed the ₹1,280 crore analyst forecast. EBITDA rose to ₹212.4 crore, bringing the margin to 15.2% from 12.1% last year—an increase of 310 basis points that outpaces the sector’s 12% average. NewPARA Segment performance: Nutrition & Health Solutions revenue climbed ₹270 crore, up 50%, with EBITDA at ₹39 crore, a 14% margin versus 12% previously. Chemical Intermediates posted ₹563 crore in sales, EBITDA ₹64 crore, a 226% surge, while Speciality Chemicals generated ₹560 crore and EBITDA ₹140 crore, reflecting a 25% margin. NewPARA Looking ahead, the board expects FY27 growth across all three segments, with a new multi‑purpose plant slated for commissioning by year‑end to support CDMO and fine chemicals. The company also acquired a 40% stake in ZettaOne Technologies for ₹189.2 crore, foreseeing 60‑70% FY27 growth and a mid‑teen EBITDA margin. NewPARA Despite the rally, Jubilant Ingrevia remains 12% lower YTD. The chemicals sector saw a modest 4.5% rise this quarter, suggesting the stock’s performance aligns with broader industry momentum but still lags the market average.